Recombinant interleukine-2 in treatment of diabetic foot syndrome

Abstract

The experience of using Roncoleukin® – recombinant interleukin-2 (rIL-2) in the complex treatment of diabetic patients with various forms of diabetic foot syndrome is summarized. The use of rIL-2 contributed to the positive dynamics of laboratory and immunological parameters and improved the results of surgical treatment, this was manifested in a decrease in the frequency of purulent-septic complications, the frequency of amputations, a decrease in the mortality rate, reducing the time of hospitalization and an improvement in long-term treatment results.